Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Dietary changes to reduce gut bacteria's impact on heart health

Official title: Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

Run by The Cleveland Clinic · NCT02016430 · Data updated 2026-11-12

This study is testing whether changing what people eat can lower a harmful compound linked to heart problems, specifically in those with high levels of it.

More Cardiovascular Risk Factor trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment170 (estimated)
SponsorThe Cleveland Clinic
Academic / other
Locations1 site (Cleveland, Ohio)
StatusRecruiting
StartedApril 4, 2014
Main results expectedDecember 2026
Study endsDecember 2026
Registry record updatedJune 25, 2026
Trial IDNCT02016430 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older with elevated TMAO levels or specific kidney function criteria.

Probably not a fit

Patients with normal TMAO levels or those unable to comply with dietary modifications may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study explores how dietary interventions can influence the production of trimethylamine-N-oxide (TMAO), a compound linked to cardiovascular risk, by gut flora. Participants with elevated TMAO levels will undergo tailored dietary modifications to assess their effectiveness in reducing TMAO generation. The study will measure TMAO levels using stable-isotope-labelled nutrients and compare results between individuals with high and normal TMAO levels. The goal is to better understand the relationship between diet, gut bacteria, and cardiovascular health.

Why it matters

Potential benefit: If successful, this study could lead to dietary strategies that significantly lower cardiovascular risk by managing gut flora metabolism.

How similar studies have gone: Previous studies have indicated a potential link between diet and TMAO levels, suggesting this approach may yield beneficial results.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Cohort 1 Inclusion criteria:

* Men and women age 18 years or above.
* Elevated TMAO metabolizers (\>5 µM) based on screening test and/or eGFR \< 60 at most recent measurement.
* Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study.
* Willing to sign the consent form and follow the study protocol, which includes a 12-week dietary modification.

Cohort 2 Inclusion criteria:

* Men and women age 18 years or above.
* Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study.
* Willing to sign the consent form and follow the study protocol.
* eGFR values ranging from 16-59

Cohort 3 Inclusion criteria:

* Men and women age 18 years or above.
* Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study.
* Willing to sign the consent form and follow the study protocol.

Exclusion Criteria (all cohorts):

* Significant chronic illness or end-organ dysfunction, including known history of uncompensated heart failure, renal failure, pulmonary disease, hematologic diseases.
* Active infection or received antibiotics within 2 months of study enrollment
* Use of over-the-counter probiotic within past month, or ingestion of yogurt within past 7 days
* Having undergone bariatric procedures or surgeries such as gastric banding or bypass.
* Pregnancy.
* Any condition which, in the judgment of the Investigator, would place a patient at undue risk by being enrolled in the trial, or cause inability to comply with the trial

Where it's running

  • Cleveland Clinic
    Cleveland, Ohio, United States
    Recruiting

Study contacts

  • Principal investigator: W. H. Wilson Tang, MD — The Cleveland Clinic
  • Study coordinator: Jennifer Wilcox, BA
  • Email: kirsopj@ccf.org
  • Phone: 216-636-6153

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.